

# **Sero-epidemiological survey on the impact of smoking on SARS-CoV-2 infection and COVID-19 outcomes – The Troina Study Protocol**

Riccardo Polosa, Venera Tomaselli, Pietro Ferrara, Alba C. Romeo, Sonja Rust, Daniela Saitta, Filippo Caraci, Corrado Romano, Murugesan Thangaraju, Pietro Zuccarello, Jed Rose, Margherita Ferrante, Jonathan Belsey, Fabio Cibella, Elisa Interlandi, Raffaele Ferri

Submitted to: JMIR Research Protocols  
on: July 21, 2021

**Disclaimer:** © The authors. All rights reserved. This is a privileged document currently under peer-review/community review. Authors have provided JMIR Publications with an exclusive license to publish this preprint on its website for review purposes only. While the final peer-reviewed paper may be licensed under a CC BY license on publication, at this stage authors and publisher expressly prohibit redistribution of this draft paper other than for review purposes.

## ***Table of Contents***

---

<b>Original Manuscript.....</b>	<b>5</b>
<b>Supplementary Files.....</b>	<b>27</b>
<b>Figures .....</b>	<b>28</b>
<b>Figure 1.....</b>	<b>29</b>



# Sero-epidemiological survey on the impact of smoking on SARS-CoV-2 infection and COVID-19 outcomes ? The Troina Study Protocol

Riccardo Polosa<sup>1,2,3</sup>; Venera Tomaselli<sup>3,4</sup>; Pietro Ferrara<sup>5,6</sup>; Alba C. Romeo<sup>7</sup>; Sonja Rust<sup>3</sup>; Daniela Saitta<sup>2,3</sup>; Filippo Caraci<sup>3,7,8</sup>; Corrado Romano<sup>7</sup>; Murugesan Thangaraju<sup>9,10</sup>; Pietro Zuccarello<sup>11</sup>; Jed Rose<sup>9,10</sup>; Margherita Ferrante<sup>3,11</sup>; Jonathan Belsey<sup>12</sup>; Fabio Cibella<sup>3,13</sup>; Elisa Interlandi<sup>14</sup>; Raffaele Ferri<sup>7</sup>

<sup>1</sup>Institute of Internal Medicine, AOU “Policlinico - V. Emanuele” Catania IT

<sup>2</sup>Department of Clinical & Experimental Medicine, University of Catania Catania IT

<sup>3</sup>Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), Università di Catania Catania IT

<sup>4</sup>Department of Political and Social Sciences, University of Catania Catania IT

<sup>5</sup>Center for Public Health Research, University of Milan – Bicocca Monza IT

<sup>6</sup>Value-based Healthcare Unit, IRCCS MultiMedica Milan IT

<sup>7</sup>Oasi Research Institute - IRCCS Troina IT

<sup>8</sup>Department of Drug and Health Sciences, University of Catania Catania IT

<sup>9</sup>Bioanalytical Laboratory, Center for Smoking Cessation, Duke University Medical Center Durham US

<sup>10</sup>Department of Psychiatry and Behavioral Sciences, Duke University Medical Center Durham US

<sup>11</sup>Department of Medical, Surgical Sciences and Advanced Technologies “G.F. Ingrassia”, University of Catania Catania IT

<sup>12</sup>JB Medical Ltd Sudbury GB

<sup>13</sup>National Research Council of Italy, Institute of Biomedicine and Molecular Immunology Palermo IT

<sup>14</sup>CIDEC Federazione Sanità Sicilia IT

## Corresponding Author:

Riccardo Polosa

Institute of Internal Medicine, AOU “Policlinico - V. Emanuele”

via S. Sofia, 78

Catania

IT

## Abstract

**Background:** After the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), research has highlighted several aspects of the pandemic, focusing on clinical features and risk factors associated with infection and disease severity. However, emerging results on the role of smoking in SARS-CoV-2 infection susceptibility or Novel Coronavirus Disease 2019 (COVID-19) outcomes are conflicting, and their robustness remains uncertain.

**Objective:** In this context, this study aims at quantifying the proportion of SARS-CoV-S antibody seroprevalence, studying the changes in antibody levels over time, and analyzing the association between the biochemically verified smoking status and SARS-CoV-2 infection.

**Methods:** The research design involves a 6-month prospective cohort study with serial sampling of the same individuals. Each participant will be surveyed about their demographics and COVID-19-related information, and blood sampling will be collected upon recruitment and at specified follow-up time points (namely, after 8 and 24 weeks). Blood samples will be screened for the presence of SARS-CoV-2 specific antibodies and serum cotinine, being the latter the principal metabolite of nicotine, which will be used to assess participants' smoking status.

**Results:** Overall, we expect to find a higher prevalence of antibodies in individuals at high-risk for viral exposure (i.e., healthcare personnel or other essential workers), according to previous literature, and to refine current estimates on the association between smoking status and SARS-CoV-2/COVID-19.

**Conclusions:** The added value of this research is that the current smoking status of the population to be studied will be biochemically verified, in order to avoid the bias associated with self-reported smoking status. As such, the results from this survey may provide actionable metric to study the role of smoking in SARS-CoV-2 infection and COVID-19 outcomes, and therefore implement the most appropriate public health measures to control the pandemic. Results may also serve as a reference for future clinical research and the methodology could be exploited in public health sectors and policies.

(JMIR Preprints 21/07/2021:32285)

DOI: <https://doi.org/10.2196/preprints.32285>

## Preprint Settings

1) Would you like to publish your submitted manuscript as preprint?

✓ **Please make my preprint PDF available to anyone at any time (recommended).**

Please make my preprint PDF available only to logged-in users; I understand that my title and abstract will remain visible to all users.

Only make the preprint title and abstract visible.

No, I do not wish to publish my submitted manuscript as a preprint.


2) If accepted for publication in a JMIR journal, would you like the PDF to be visible to the public?

✓ **Yes, please make my accepted manuscript PDF available to anyone at any time (Recommended).**

Yes, but please make my accepted manuscript PDF available only to logged-in users; I understand that the title and abstract will remain visible to all users.

Yes, but only make the title and abstract visible (see Important note, above). I understand that if I later pay to participate in [JMIR Publications](#)

**Original Manuscript**



## Sero-epidemiological survey on the impact of smoking on SARS-CoV-2 infection and COVID-19 outcomes – The Troina Study Protocol

R. Polosa<sup>1,2,3</sup>, V. Tomaselli<sup>3,4</sup>, P. Ferrara<sup>5,6</sup>, A. C. Romeo<sup>7</sup>, S. Rust<sup>3</sup>, D. Saitta<sup>2,3</sup>, F. Caraci<sup>3,7,8</sup>, C. Romano<sup>7</sup>, M. Thangaraju<sup>9,10</sup>, P. Zuccarello<sup>11</sup>, J. Rose<sup>9,10</sup>, M Ferrante<sup>3,11</sup>, J. Belsey<sup>12</sup>, F. Cibella<sup>3,13</sup>, E. Interlandi<sup>14</sup>, R. Ferri<sup>7</sup>

1. Institute of Internal Medicine, AOU “Policlinico - V. Emanuele”, Catania, Italy
2. Department of Clinical & Experimental Medicine, University of Catania, Italy
3. Center of Excellence for the Acceleration of Harm Reduction (CoEHAR), University di Catania, Italy
4. Department of Political and Social Sciences, University of Catania, Italy
5. Center for Public Health Research, University of Milan – Bicocca, Monza, Italy
6. IRCCS MultiMedica, Milan, Italy
7. Oasi Research Institute - IRCCS, Troina, Italy
8. Department of Drug and Health Sciences, University of Catania, Italy
9. Bioanalytical Laboratory, Center for Smoking Cessation, Duke University Medical Center, Durham, USA
10. Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, USA
11. Department of Medical, Surgical Sciences and Advanced Technologies “G.F. Ingrassia”, University of Catania, Italy
12. JB Medical Ltd, Sudbury, UK
13. National Research Council of Italy, Institute of Biomedicine and Molecular Immunology, Palermo, Italy.
14. CIDEC Federazione Sanità

### *Corresponding author*

Prof. Riccardo Polosa

AOUP “G. Rodolico - San Marco” - via S. Sofia, 78

Email: polosa@unict.it

Tel: +39.095.378.1566/1583

Fax: +39.095.378.1567

## Abstract

*Background:* After the global spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), research has highlighted several aspects of the pandemic, focusing on clinical features and risk factors associated with infection and disease severity. However, emerging results on the role of smoking in SARS-CoV-2 infection susceptibility or Novel Coronavirus Disease 2019 (COVID-19) outcomes are conflicting, and their robustness remains uncertain.

*Objective:* In this context, this study aims at quantifying the proportion of SARS-CoV-2 antibody seroprevalence, studying the changes in antibody levels over time, and analyzing the association between the biochemically verified smoking status and SARS-CoV-2 infection.

*Methods:* The research design involves a 6-month prospective cohort study with serial sampling of the same individuals. Each participant will be surveyed about their demographics and COVID-19-related information, and blood sampling will be collected upon recruitment and at specified follow-up time points (namely, after 8 and 24 weeks). Blood samples will be screened for the presence of SARS-CoV-2 specific antibodies and serum cotinine, being the latter the principal metabolite of nicotine, which will be used to assess participants' smoking status.

*Results:* The study is ongoing. It aims to find a higher antibody prevalence in individuals at high-risk for viral exposure (i.e., healthcare personnel), and to refine current estimates on the association between smoking status and SARS-CoV-2/COVID-19.

*Conclusions:* The added value of this research is that the current smoking status of the population to be studied will be biochemically verified, in order to avoid the bias associated with self-reported smoking status. As such, the results from this survey may provide actionable metric to study the role of smoking in SARS-CoV-2 infection and COVID-19 outcomes, and therefore implement the most appropriate public health measures to control the pandemic. Results may also serve as a reference for future clinical research and the methodology could be exploited in public health sectors and policies.

**Keywords:** antibody persistence; cotinine; COVID-19; SARS-CoV-2; seroprevalence; smoking impact; smoking status.

## Introduction

## Overview

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel coronavirus strain that was first reported as a cluster of viral pneumonia cases of unknown etiology in Wuhan, the capital city of the Hubei Province in China on December 31, 2019. The spreading of SARS-CoV-2 reached pandemic proportion in March 2020, and as of the April 2021 more than 141 million cases had been confirmed, and more than 3 million fatalities had occurred worldwide [1].

In late February 2020, the first non-imported cases of COVID-19 were identified in Italy. Since then, SARS-CoV-2 spread rapidly to the community, as reported by national health authorities [2]. On May 23, 2020, at the time of project proposal design, the Italian Ministry of Health reported that of the 229,327 people who had contracted the virus, 57,752 were still positive (of whom 8,695 were hospitalised with symptoms - 15%; 572 were admitted in intensive care units (ICU) - 1,0%; and the remaining 48,485 were self-isolating at home - 84%), 32,735 had died (14.3%) and 138,840 healed (60.5%) on a total of 2,164,426 tested cases [3]. As of April 2021, 3,870,131 cases and 116,927 deaths have been recorded in the country [4].

Since the beginning of the pandemic, the global scientific community was engaged in intense research efforts to understand all aspects of this public health crisis, from the clinical features of the disease and risk factors for adverse outcome, the patterns of viral spread in the population, the role of asymptomatic or subclinical cases in human-to-human transmission, and the serological response. The clinical features of the novel coronavirus disease 2019 (COVID-19) range from a self-limited flu-like syndrome to progressive lung involvement with respiratory failure and widespread systemic effects [5-7]. Epidemiological surveillance has primarily focused on hospitalized patients with severe disease, and, as such, the full spectrum of the disease, including the extent and proportion of mild or asymptomatic infections is less clear. Evidence suggests that asymptomatic or oligo-symptomatic infection is not uncommon [8-11]. A recent review reported that at least one third of SARS-CoV-2 infections are asymptomatic and that almost three quarters of persons who are asymptomatic at the time of a positive PCR test result will remain asymptomatic [12]. Remarkably, sequelae of previous viral pneumonia have been reported in chest CT scans of asymptomatic individuals [13] and SARS-CoV-2 transmission from asymptomatic cases to others has been documented [13,14].

In this frame, a seroprevalence study is an ideal attempt for measuring the true infection rates in general or specific populations [11,15,16] In Italy, a nationwide survey was conducted by the



National Institute of Statistics (ISTAT), reporting an IgG seroprevalence of 2.5% [17]. However, there is limited use of seroprevalence studies in order to retrospectively identify potential predictors of infection susceptibility and disease severity, both in the general population and in specific sub-groups (such as smokers, pediatric populations, elders).

Several risk factors for severe COVID-19 have been identified, including cardiovascular disease, diabetes, obesity, and COPD [18-21]. Intuitively, one important additional risk factor is expected to be cigarette smoking. Smokers have a higher risk for developing viral and bacterial respiratory infections [22-24], being five times more likely to have influenza and twice more likely to develop pneumonia [25].

However, the role of smoking in SARS-CoV-2 infection susceptibility and COVID-19 outcomes is still unclear. While there appears to be a higher risk for ICU admission and adverse outcomes [26-28], it has been reported that the prevalence of smoking among hospitalized COVID-19 patients is far lower than would be expected based on population smoking prevalence [29-32]. These findings were initially derived from Chinese case series, and while it is possible that the prevalence of smokers in Chinese case series may be underrepresented due to inaccurate recording of their smoking status, similar findings have been reported in France [30], Germany [33], Italy [34], and in the United States [32,35].

It is not clear how far the underrepresentation of smokers among COVID-19 inpatients reflects problems with poor reporting of the smoking status. Given the challenging circumstances of the pandemic, recall or reporting bias cannot be excluded. The possibility for inaccurate recording, false-reporting or underreporting of the smoking status due to the extremely challenging situations at wards/ICUs with work overloads and operating in a persistent state of emergency should not be underestimated. Improving the quality of clinical and behavioral data mandates the need for an accurate and dedicated recording of the smoking status. Alternatively, population-level data collected outside of hospital settings are required. Another important limitation is that most of the observations were unadjusted for smoking-related comorbidities, which are known to be associated with higher risk for an adverse outcome in COVID-19 patients [18]. Lack of adjustment for relevant confounders means it is not possible to disentangle the effect of smoking. Addressing all these limitations is important for evaluating clinical risk, developing clear public health messages, and identifying targets for intervention.

### ***Research objectives***

Surveillance of antibody seropositivity in a population can allow inferences to be made about the cumulative incidence of infection in the population. Additionally, little is currently known about antibody kinetics. Asymptomatic infected persons may clear the virus more quickly than do symptomatic patients, and antibody titers in the former are likely to be lower, if they seroconvert at all, than in infected symptomatic patients [11,36]. Furthermore, understanding the association between smoking and SARS-CoV-2 infection susceptibility or COVID-19 outcomes is generally limited and of poor quality.

To summarize, there is a need for robust, population-based evidence on the association of smoking with SARS-CoV-2 infection and COVID-19 outcomes, adjusting for potential confounding variables (e.g., sociodemographic characteristics, key worker status, and comorbid health conditions), and a population seroprevalence study could be useful for this goal. The following key research questions will be addressed:

1. Does smoking increase susceptibility to SARS-CoV-2 infection?
2. Does smoking increase susceptibility to COVID-19 outcomes?
3. Does smoking affect the serological response after SARS-CoV-2 infection?

### ***Research Proposal***

We propose a 6-months prospective study using in combination a random population sample (taken from residents of the town of Troina; the town with the highest prevalence of positive SARS-CoV-2 cases in Sicily at the time of drafting the protocol in March-May 2020)

and a convenience sample (taken from staff of the Troina's main health care establishment, reported to have high infectious levels in the same time period), to investigate the prevalence of past infection, as determined by seropositivity (anti-SARS-CoV-2 specific IgG by enzyme linked immunosorbent assay [ELISA]). The biochemically-verified smoking status of the study population (i.e. serum cotinine) will be correlated with serological data and COVID-19 outcomes (i.e., clinical symptoms and hospitalization).

### ***Study aim***

Epidemiological exposure data and venous blood (for measurements of anti-SARS-CoV-2-specific IgG and serum cotinine levels) will be systematically collected. Demographic, medical history and epidemiological exposure data will be recorded from specifically designed questionnaires (for COVID-19 outcomes, relevant comorbidities, and smoking status) and shared rapidly in a format that can be easily aggregated, tabulated and analyzed across many different regional (or national

and international) settings for timely estimates of COVID-19 virus infection and its immunologic response rates according to the smoking status, as well as to inform public health responses and policy decisions.

## Methods

### *Specific aims*


In summary, the main objectives of the study will be to:

- 1 Quantify the proportion of SARS-CoV-2 infected people (by serology assessment of anti- SARS-CoV-2 IgG levels) in a random population sample at baseline;
- 2 Quantify the proportion of SARS-CoV-2 infected people (by serology assessment of anti- SARS-CoV-2 IgG levels) in a convenience sample (hospital staff) at baseline;
- 3 Quantify the proportion of participants with asymptomatic SARS-CoV-2 infection;
- 4 Quantify the proportion of mildly-to-moderately symptomatic (management at home) COVID-19 cases among all participants;
- 5 Quantify the proportion of severely symptomatic (management at hospital) COVID-19 cases among all participants;
- 6 Quantify the proportion of biochemically verified (by serum cotinine) current, former and never smokers among all participants (random population sample + convenience sample);
- 7 Quantify the proportion and analyze the association between smoking status (current, former and never smokers) and:
  - a. *SARS-CoV-2 infection (asymptomatic and symptomatic combined);*
  - b. *asymptomatic SARS-CoV-2 infection;*
  - c. *mild-to-moderate COVID-19 disease (management at home);*
  - d. *severe COVID-19 disease (hospitalization needed);*
- 8 Record relevant clinical confounders known to be associated with COVID-19 outcomes;
- 9 Compare anti- SARS-CoV-2 IgG levels at baseline among current, former and never smokers;
- 10 Monitor and compare anti- SARS-CoV-2 IgG levels changes from baseline to 2-months and 6-months among current, former and never smokers.

### *Study design*

This study will investigate the association between biochemically verified smoking status of the

study population and serological data as well as COVID-19 outcomes (i.e., clinical symptoms and hospitalization). The research design involves a 6-month prospective multiple cohort study with serial sampling of the same individuals each time. Sampling will be commenced in July and repeated at 8 weeks (Figure 1). A final follow-up visit will be carried out at 24 weeks.



### Study population and setting

Within the geographic scope of the study, high incidence of positive cases was identified in the general population of Troina, a town of around 9,000 inhabitants in the province of Enna, in the center of Sicily. This town was hit hardest in terms of COVID-19 cases during the first wave in Italy [2-4] - with hundreds of cases registered in the very first epidemic weeks in March 2020 [37,38] - , and was declared 'red zone' on March 29, 2020 with the enforcement of lockdown retractions in that area [38]. The study population will consist of a population-based, age-stratified cohort in Troina that will be sampled through random selection of town residents. Identification and recruitment of participants will expand over different age groups in order to determine and compare age-specific attack rates. For logistic reasons, specimen and data collection will be performed at a single location, asking participants to travel to that location to participate in the study. Targeted testing will also be extended to a convenience sample consisting of about 600 staff members of Troina's main health care establishment (high risk individuals).

### ***Eligibility criteria***

Any individual identified for recruitment, irrespective of age, can participate. Exclusion criteria will be refusal to provide informed consent, or contraindication to venipuncture. Suspected or confirmed active/acute or prior SARS-CoV-2 infection should not be considered as an exclusion criterion for this investigation. Doing so would underestimate the extent of infection in the population. For individuals currently receiving medical care for COVID-19 infection, a family member or proxy may be used to complete the questionnaire on his/her behalf.

### ***Smoking status definition***

Current smokers will be defined as those who report that they smoke and have serum cotinine levels  $\geq 20$  ng/mL. Former smokers will be defined as those who report that they used to smoke in the past but not now and have serum cotinine levels  $< 20$  ng/mL. Never smokers will be defined as those who report that they never smoked smoke in the past and have serum cotinine levels  $< 20$  ng/mL.

### ***Data collection***

Each participant recruited into the study will be asked to complete a questionnaire which will record the following information: demographics, information about known COVID-19 disease and relevant clinical course, comorbidities, and smoking status (see attached).

### ***Specimen collection***

A small amount of blood (10 mL) will be collected from each participant upon recruitment (T0) and at specified follow-up time points (T8wks, T24wks).

### ***Specimen transport and Biobanking***

For each biological sample collected, the time of collection, the conditions for transportation and the time of arrival at the study laboratory will be recorded. Specimens should reach the laboratory as soon as possible after collection. Serum should be separated from whole blood and stored at  $-20^{\circ}\text{C}$  or lower and shipped on dry ice. A biobanking facility will be established in Troina.

### ***Sample storage***

Prior to testing, serum samples will be stored at  $-80^{\circ}\text{C}$  at the reference biobanking facility. It is recommended to aliquot samples prior to freezing, to minimize freeze thaw cycles.

### ***Serological testing***

Serologic assays of high sensitivity and specificity for SARS-CoV-2 have been recently validated and published. Serum samples will be screened for the presence of SARS-CoV-2 specific antibodies using

a quantitative ELISA test for anti-SARS-CoV-2 IgG (Euroimmun, CND W0105040619) [39]. Serum samples will be stored at  $-80^{\circ}\text{C}$  until use. and the assay will be performed according to the manufacturer's protocol. The neutralization capability, specificity and sensitivity of the test have been thoroughly investigated and published together with assay validation [40]. Reagent wells of the assays are coated with recombinant structural protein (S1 domain) of SARS-CoV-2. The optical density (OD) will be detected at 450 nm, and a ratio of the reading of each sample to the reading of the calibrator, included in the kit, will be calculated for each sample (OD ratio). The cut-off value for IgG OD ratio is 0.3. Following blocking, diluted serum (1:100 or 2-fold serially diluted for titers) will be added and incubated at  $37^{\circ}\text{C}$  for 1h in the 96-well microtiter ELISA plates. Antigen-specific antibodies will be detected using peroxidase-labeled rabbit anti-human IgG and TMB as a substrate. The absorbance of each sample will be measured at 450 nm. Laboratory procedures involving sample manipulation must be carried out in a biosafety cabinet.

### ***Cotinine Assay***

About 1mL of serum will be pipetted into 10 ml tubes and 100 ng/mL of Ortho-cotinine used as internal standard will be added. Then, about 50 $\mu\text{L}$  of 0.1M aqueous sodium hydroxide solution will be added to the culture tube followed by 325 $\mu\text{L}$  of Chloroform. The tube will be secured with cap and Vortex mixed for ~3 minutes (using VX 2500 Multi Tube Vortex Mixer) and centrifuged for ~4 minutes (in Beckmann Allegra centrifuge) at 2500 rpm. Using a glass Pasteur Pipette, the top aqueous layer will be removed and discarded into the hazardous waste container and the organic layer will remain in the tube. About ~100mg (0.1g) of anhydrous sodium sulfate will be added to the organic layer and allowed to rest for ~3 minutes (which will allow the sodium sulfate to absorb any water that may be present in the organic layer). In the end, the clear organic layer (with no water) will be carefully removed (without disturbing the settled sodium sulfate), concentrated to ~100  $\mu\text{L}$  vial insert and placed in a GC vial. The concentrated sample will be capped and arranged on to auto sampler tray for GC injection. One microliter ( $\mu\text{L}$ ) of each sample will be injected into HP-5 Capillary GC Column (0.32 mm ID, 25 m length and 0.52 $\mu\text{m}$  film thickness; bonded 5% phenyl and 95% dimethylpolysiloxane) of GC-NPD. The inlet temperature will  $250^{\circ}\text{C}$  at split-less mode. The initial oven temperature will be  $70^{\circ}\text{C}$  with 1-minute hold and then increased to  $230^{\circ}\text{C}$  at the rate of  $25^{\circ}\text{C}/\text{minute}$ . Every batch of sample will be run with 6 calibration levels (20, 50, 100, 200, 400, 600 ng/mL), 4 quality controls (20, 100, 400, 600 ng/mL) and 1 blank control for accurate quantification. The amount of cotinine will be reported in ng/mL The limit of quantification (LOD) of cotinine is 20

ng/mL.

### **Statistical Plan**

Estimates of margin of error as a function of seroprevalence are low for 300 samples. We will be aiming for > 1000 samples of a representative sample of the population by gender and age groups (0-17 years, 18-65 years, and 66 years and over).

For the enrolment of participants into the study the following inclusion and exclusion criteria need to be fulfilled.

Inclusion in population criteria:

- Aged into the above groups;
- Living in the town of interest;
- Willing to participate in the baseline and to be re-contacted for follow-up waves.

Exclusion from population criteria:

- Persons belonging to the institutionalized population.

Exclusion from sample (censoring) criteria:

- Moved to another village during the study period;
- Those stating explicitly their wish not to be re-contacted for this study.

In order to correctly represent the population involved, the age groups of interest have been assigned to three different categories by gender in terms of population size. A corresponding targeted sample size for this study is specified for each category.

In the entire population, we estimated several sample sizes depending on the margin of error equal to 0.03, 0.04, or 0.05 for estimate proportions of sampled population, as shown in Table 1.

<b>Table 1. The Troina Study - Sample size calculation</b>					
			<i>Margin of error</i> 3%	<i>Margin of error</i> 4%	<i>Margin of error</i> 5%
<b>Age groups</b>	<b>Gender</b>	<b>N</b>	(N*1308) / TOTAL 9094 = n	(N*613) / TOTAL 9094 = n	(N*384) / TOTAL 9094 = n
0-17 years	Male	694	100	47	29
	Female	648	93	44	27
	<b>Total</b>	<b>1342</b>	<b>193</b>	<b>90</b>	<b>57</b>
18-65 years	Male	2751	396	185	116
	Female	2803	403	189	118
	<b>Total</b>	<b>5554</b>	<b>799</b>	<b>374</b>	<b>235</b>
> 65 years	Male	961	138	65	41
	Female	1237	178	83	52
	<b>Total</b>	<b>2198</b>	<b>316</b>	<b>148</b>	<b>93</b>

TOTAL	Male	4406	634	297	186
	Female	4688	674	316	198
	<b>Total</b>	<b>9094</b>	<b>1.308</b>	<b>613</b>	<b>384</b>

We will draw a multi-layered sample with a confidence level of 0.97% in order to minimize the margin of error to 3% and ensure the best reliability of the sample data. The planned total sample size comprises up to 1,308 participants at recruitment stage. The attrition rate is estimated at 10%. Information will be collected in a standardized format according to the questionnaires and tools in the protocol (see attached). The data shared should include only the study identification number and not any personal identifiable information. We will report the following information:

- . (1) the number of households and the number of individuals included;
- . (2) the age and sex of all individuals included;
- . (3) the antibody levels in the sample of all individuals included;
- . (4) the number of individuals with serologic evidence of COVID-19 virus infection (stratified by age);
- . (5) the number of individuals with serologic evidence of COVID-19 virus infection who have reported symptoms;
- . (6) the number of individuals with known previous SARS-CoV-2 infection who were hospitalized or recovered at home;
- . (7) the number of individuals with serologic evidence of COVID-19 virus infection who are current, former and never smokers (biochemically verified by serum cotinine assay).

Socio-demographic and baseline characteristics will be summarised for the Troina population, the convenience sample and for the total sample recruited. Categorical variables will be reported as numbers and proportions with 95% confidence intervals (CI). Between-groups comparisons will be carried out using chi-square testing or Fisher's exact test, as appropriate. Continuous variables will be reported as means and standard deviations and as medians and interquartile ranges. Between-groups comparisons will be carried out using tests like ANOVA, Mann-Whitney U test or Wilcoxon-signed rank test, as appropriate. The proportions of patients developing a positive PCR test for SARS-CoV-2 result over the course of the study will be reported as numbers and proportions with 95% CIs, separated by subgroups identifying those with symptomatic or asymptomatic infection. Data on change in antibody levels from baseline to follow-up will be presented for the whole recruited population. Statistical significance of change will be estimated using repeated-measures T-



testing. Correlation between smoking status and the risk of COVID-19 infection will be tested using a 3x2 Chi-square test of independence. A p-value  $\leq .05$  will be considered to represent the threshold of statistical significance for all comparisons.

### ***Data collection procedures***

In order to accomplish the specific aims of the project, data will be stored in a database system, after each completed collection step, and transfer to central data management for further data processing and merging. Each participant will be assigned a unique identification code consisting of a number identifier which will be used for data merging. After data collection, data validation checks will be performed as agreed in a data validation plan, and data cleaning procedures will be used as applicable to ensure best achievable quality of data for analysis purposes. Only the study staff working with the fieldwork provider will be able to identify the participants based on the identification codes. Only de-identified data will be transferred from the field work provider to the central data management. All electronic data files will be kept on secure servers with backup processes in place. Personal data of participants must be strictly kept separately from study data and is accessed only by authorized staff for the purposes of the study conduct. Before starting data collection, the involved staff will receive training on the background and objectives of this study, on eligibility criteria, on the participant selection procedure, on ethical obligations, on completion and validation of the procedure, as well as on the data collection platform. Local field work staff will be trained for each relevant data collection process and logistic related procedure.

Eligible subjects are informed about the study purpose, their requested tasks, time of involvement, data confidentiality and data protection. Once they stated their willingness to participate, they will proceed with the screening and study enrolment. Enrolled subjects have the right to stop their participation at any time without any penalty. Preferably, the reason for premature end of participation will be recorded. Participants who drop-out will not be replaced. Every effort will be made to protect participant confidentiality according to the GDPR.

### **Results**

We expect to find a higher prevalence of antibodies in individuals at high-risk for viral exposure (i.e., healthcare personnel and other essential workers) according to previous evidence, and to refine current estimates on the association between smoking status and SARS-CoV-2/COVID-19. A total of 1785 subjects have been enrolled in the study. Data cleaning and analyses are ongoing.

## Discussion

This project is the first population-based study that uses seroprevalence data and an objective assessment of the current smoking status in order to examine the association between smoking and SARS-CoV-2 infection susceptibility and severity. Additionally, the study will examine for the first time the magnitude of the seroconversion response in current smokers, compared to former and never smokers as well as the changes in antibody titers over time according to the smoking status. Instead of focusing on hospitalized patients only, the study will also include participants who infected individuals who were either asymptomatic or had COVID-19 but were not hospitalized. It will also consider confounding factors in the association between smoking and SARS-CoV-2 that were not addressed in previous research. Finally, the results from this survey may serve as a reference to other contexts and provide actionable metric to quantify and offer a clear overview of SARS-CoV-2 spread, and the methodology and findings can be exploited in public health research and policies to minimize the disease impact and implement the most appropriate prevention measures to protect susceptible population.

## List of abbreviation

COVID-19: novel coronavirus disease 2019

COPD: chronic obstructive pulmonary disease

ELISA: enzyme-linked immunosorbent assay

ICU: intensive care unit

IgG: immunoglobulin G

IgM: immunoglobulin G

ISTAT: Italian National Institute of Statistics

LOD: limit of quantification

OD: optical density

PCR: polymerase chain reaction

REC: Research Ethics Committee

SARS-CoV-2: severe acute respiratory syndrome coronavirus 2

## DECLARATIONS

### ETHICAL AND CONFIDENTIALITY CONSIDERATIONS

#### Research Ethics Committee (REC) review

- Before the start of the study, approval will be sought from the local REC (Comitato Etico IRCCS Sicilia - Oasi Maria SS) for the study protocol, informed consent forms and other relevant documents e.g. advertisements and GP information letters.
- Substantial amendments that require review by REC will not be implemented until the REC grants a favorable opinion for the study.
- A final report with the results will be submitted to the REC within 90 days of the date on which the study is declared ended.

#### Participants' Consent

The Principal Investigator (PI) will retain overall responsibility for the conduct of research; this includes obtaining informed consent from the participants. They must ensure that any person delegated responsibility to participate in the informed consent process is duly authorized, trained and competent to participate according to the ethically approved protocol, Principles of Good Clinical Practice and Declaration of Helsinki.

At baseline visit (V0), potential participants will be provided with a verbal explanation of the study and practical details, accompanied by a written patient information sheet stating that the investigation poses minimal risk, involves the collection of a small amount of blood (10 ml) and personal information on a questionnaire. Once eligibility has been established and consent formed signed, procedures will be completed (venipuncture and questionnaires). Subjects will be booked for the next follow-up visit.

#### Data protection and patient confidentiality

All investigators and study site staff will comply with the requirements of the Data Protection Act 2018 and GDPR, with regards to the collection, storage, processing and disclosure of personal information. Participant confidentiality will be maintained throughout the investigation. In particular:

- The paper clinical record files/ data will be stored in a locked cabinet;
- Each participant will be allocated a unique study identification number. The clinical record will have no identifying patient information on (Patient ID/ Name/ Address/ Date of Birth). The patients will be referred to by their unique study identification number instead;
- Participants' personal details will not be attached to their research results and the decoding list will only be available to a limited number of members of the research team;
- All information that is obtained during the study procedures will be treated as private and confidential;
- Only the researchers involved in the study will have access to the participants' data relating to the research project;
- Analysis of the data will be undertaken by independent researchers at University of Catania. The study data will all be anonymized and participants will be referred to only by their unique study Identification Number. Published results will only present aggregated, anonymous results and no individuals will be identifiable.

### **Consent for publication**

*Not applicable.*

### **Availability of data and materials**

*The data that support the findings of this study are available from the corresponding author, RP, upon reasonable request.*

### **Competing interests**

RP is full tenured professor of Internal Medicine at the University of Catania (Italy) and Medical Director of the Institute for Internal Medicine and Clinical Immunology at the same University. In relation to his recent work in the area of respiratory diseases, clinical immunology, and tobacco control, RP has received has received lecture fees and research funding from Pfizer, GlaxoSmithKline, CV Therapeutics, NeuroSearch A/S, Sandoz, MSD, Boehringer Ingelheim, Novartis, Duska Therapeutics, and Forest Laboratories. Lecture fees from a number of European EC industry and trade associations (including FIVAPE in France and FIESEL in Italy) were directly donated to

vaper advocacy no-profit organizations. RP has also received grants from European Commission initiatives (U-BIOPRED and AIRPROM) and from the Integral Rheumatology & Immunology Specialists Network (IRIS) initiative. He has also served as a consultant for Pfizer, Global Health Alliance for treatment of tobacco dependence, CV Therapeutics, Boehringer Ingelheim, Novartis, Duska Therapeutics, ECITA (Electronic Cigarette Industry Trade Association, in the UK), Arbi Group Srl., and Health Diplomats. RP has served on the Medical and Scientific Advisory Board of Cordex Pharma, Inc., CV Therapeutics, Duska Therapeutics Inc, Pfizer, and PharmaCielo. RP is also founder of the Center for Tobacco prevention and treatment (CPCT) at the University of Catania and of the Center of Excellence for the acceleration of Harm Reduction (CoEHAR) at the same University, which has received support from Foundation for a Smoke Free World to conduct 8 independent investigator-initiated research projects on harm reduction. RP is also currently involved in the following pro bono activities: scientific advisor for LIAF, Lega Italiana Anti Fumo (Italian acronym for Italian Anti-Smoking League), the Consumer Advocates for Smoke-free Alternatives (CASAA) and the International Network of Nicotine Consumers Organizations (INNCO); Chair of the European Technical Committee for standardization on “Requirements and test methods for emissions of electronic cigarettes” (CEN/TC 437; WG4). JR: Research support from Foundation for a Smoke-Free World, Philip Morris International, Altria, JUUL Labs. Consulting with Revive pharmaceuticals, and consulting and patent purchase agreement with Philip Morris International. All other authors have no relevant conflict of interest to declare in relation to this study.

### **Funding Source**

This investigator research protocol was sponsored by ECLAT SRL, a spin-off of the University of Catania, through a grant from the Foundation for a Smoke-Free World, a US nonprofit 501(c)(3) private foundation with a mission to end smoking in this generation. The Foundation accepts charitable gifts from PMI Global Services Inc.; under the Foundation’s Bylaws and Pledge Agreement with PMI Global Services Inc., the Foundation is independent from PMI Global Services Inc. and the tobacco industry. The contents, selection, and presentation of facts, as well as any opinions expressed herein are the sole responsibility of the authors and under no circumstances shall be regarded as reflecting the positions of the Foundation for a Smoke-Free World, Inc. ECLAT SRL is a research-based company from the University of Catania that delivers solutions to global health problems with special emphasis on harm minimization and technological innovation.

## Authors' contributions

Riccardo Polosa, conceived the study, contributed to its design, drafted and finalized the manuscript. V. Tomaselli, contributed to the design of the study, with particular input on analysis and interpretation of data. P. Ferrara, contributed to the design of the study and revised the manuscript. A.C. Romeo, contributed to the design of the study, and will be involved in the project management to organize and coordinate the data collection process. S. Rust, contributed with input on analytical testing, and will be involved in the project management to organize and coordinate the data collection process. D. Saitta, contributed to the design of the study, and will be involved in the project management and central coordination. F. Caraci, contributed to the design of the study and revised the manuscript. C. Romano, contributed to the design of the study and revised the manuscript. M. Thangaraju, contributed with input on analytical testing. P. Zuccarello, contributed with input on analytical testing. J. Rose, contributed with input on analytical testing and revised the manuscript. M. Ferrante, contributed with input on analytical testing. J. Belsey, contributed to the design of the study, with particular input on analysis and interpretation of data. F. Cibella, contributed to the design of the study, with particular input on analysis and interpretation of data. E. Interlandi, contributed to the design of the study, and will be involved in the project management to organize and coordinate the data collection process. R. Ferri, contributed to the design of the study and revised the manuscript.

## Acknowledgements

The authors would like to thank Jas Mantero (European Centre for Disease Prevention and Control) and Mark Smolinski (Ending Pandemics) for the constructive feedback about the protocol, Alessia Visalli (Euroimmun Italia Srl.) for the technical discussion about specificity and sensibility of anti-SARS-CoV-2 IgG, and Adrian Shalivari (Fullcro Srl, Roma, Italy) for the development of the electronic data capture system. The authors would also like to thank Concita Santoro, Annemarie Linder, the Mayor of Troina, Fabio Venezia, Chief of Staff of Protezione Civile, Alessandro Nasca, and all the volunteers of Protezione Civile for their help and assistance.

## REFERENCES

1. World Health Organization. WHO Coronavirus Disease (COVID-19) Dashboard. Available at: <https://covid19.who.int> (last accessed on April 18, 2021)
2. Istituto Superiore di Sanità. Sorveglianza integrata COVID-19. Available at: <https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati> (last accessed on April 18, 2021)
3. Dipartimento della Protezione Civile. COVID-19 Italia - Monitoraggio della situazione. Available at: [www.opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaa-c82fe38d4138b1](http://www.opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaa-c82fe38d4138b1) (last accessed on April 18, 2021)
4. Balasco N, d'Alessandro V, Ferrara P, et al. Analysis of the time evolution of COVID-19 lethality during the first epidemic wave in Italy. *Acta BioMedica* 2021;92(2): e2021171. doi: 10.23750/abm.v92i2.11149
5. World Health Organization (2020) Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. <https://www.who.int/docs/default-source/coronaviruse/clinical-management-of-novel-cov.pdf>
6. Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. *The Lancet Respiratory Medicine* 2020;8(4):420-422
7. Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. *Cardiovascular Research* 2020;116(10):1666-1687
8. Zhu J, Ji P, Pang J, et al. Clinical characteristics of 3,062 COVID-19 patients: a meta-analysis. *J Med Virol.* 2020;92(10):1902-1914
9. Roxby AC, Greninger AL, Hatfield KM, et al. Detection of SARS-CoV-2 Among Residents and Staff Members of an Independent and Assisted Living Community for Older Adults - Seattle, Washington, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69(14):416-418
10. Hu Z, Song C, Xu C, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. *Sci China Life Sci.* 2020;63(5):706-711.

11. Della Valle P, Fabbri M, Madotto F, et al. Occupational Exposure in the Lombardy Region (Italy) to SARS-CoV-2 Infection: Results from the MUSTANG-OCCUPATION-COVID-19 Study. *International Journal of Environmental Research and Public Health*. 2021;18(5):2567
12. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review. *Ann Intern Med*. 2021;174(5):655-662
13. Wang Y, Tong J, Qin Y, et al. Characterization of an asymptomatic cohort of SARS-CoV-2 infected individuals outside of Wuhan, China. *Clin Infect Dis*. 2020;ciaa629
14. Huang L, Zhang X, Zhang X, et al. Rapid asymptomatic transmission of COVID-19 during the incubation period demonstrating strong infectivity in a cluster of youngsters aged 16-23 years outside Wuhan and characteristics of young patients with COVID-19: A prospective contact-tracing study. *J Infect*. 2020;80(6):e1-e13
15. Sakurai A, Sasaki T, Kato S, et al. Natural history of asymptomatic SARS-CoV-2 infection. *N Engl J Med* 2020;383:885-86
16. Hung IF, Cheng VC, Li X, et al. SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series. *Lancet Infect Dis* 2020;20:1051-60
17. Istituto Nazionale di Statistica (ISTAT). Primi risultati dell'indagine di sieroprevalenza SARS-CoV-2. Available at: <https://www.istat.it/it/files/2020/08/ReportPrimiRisultatiIndagineSiero.pdf> (last accessed on April 18, 2021)
18. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020;395(10229):1054-1062
19. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis. *Eur Respir J*. 2020;55(5):2000547
20. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. *New England Journal of Medicine* 2020;382:e102
21. Caci G, Albini A, Malerba M, Noonan DM, Pochetti P, Polosa R. COVID-19 and Obesity: Dangerous Liaisons. *J Clin Med*. 2020;9(8):2511
22. Arcavi L, Benowitz NL. Cigarette Smoking and Infection. *Archives of Internal Medicine* 2004;164, 2206-2216




23. Stämpfli MR, Anderson GP. How cigarette smoke skews immune responses to promote infection, lung disease and cancer. *Nature Reviews Immunology* 2009;9:377-384
24. Feldman C, Anderson. Cigarette smoking and mechanisms of susceptibility to infections of the respiratory tract and other organ systems. *J Infect* 2013;67(3):169–184
25. Royal College of Physicians. Hiding in plain sight: Treating tobacco dependency in the NHS (2018). Available at: <https://www.rcplondon.ac.uk/projects/outputs/hiding-plain-sight-treating-tobacco-dependency-nhs>
26. Vardavas CI, Nikitara K. COVID-19 and smoking: A systematic review of the evidence. *Tob Induc Dis.* 2020;18:20. Published 2020 Mar 20. doi:10.18332/tid/119324
27. Simons D, Shahab L, Brown J, Perski O. The association of smoking status with SARS-CoV-2 infection hospitalization and mortality from COVID-19: A living rapid evidence review. *Qeios* 2020 Apr 23, <https://www.qeios.com/read/article/582>
28. Liu W, Tao ZW, Wang L, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. *Chin Med J (Engl).* 2020;133(9):1032-1038
29. Lippi G, Henry BM. Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19). *Eur J Intern Med.* 2020; 75: 107–108
30. Miyara M, Tubach F, Pourcher V, et al. Low incidence of daily active tobacco smoking in patients with symptomatic COVID-19. *Qeios* 2020 Apr 21, <https://www.qeios.com/read/article/574>
31. Farsalinos K, Barbouni A, Poulas K, et al. Current smoking, former smoking, and adverse outcome among hospitalized COVID-19 patients: a systematic review and meta-analysis. *Ther Adv Chronic Dis.* 2020;11:1–14
32. Chow N, Fleming-Dutra K, Gierke R, Hall A. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020. *MMWR Morb Mortal Wkly Rep.* 2020;69:382–386
33. Dreher M, Kersten A, Bickenbach J, et al. Charakteristik von 50 hospitalisierten COVID-19-patienten mit und ohne ARDS. *Dtsch Arztebl Int* 2020;117:271–278
34. Gaibazzi N, Tuttolomondo D, Guidorossi G, Botti A, Tedeschi A, Martini C, Mattioli M. Smoking Prevalence is Low in Symptomatic Patients Admitted for COVID-19. *medRxiv* 2020,


15 May <https://doi.org/10.1101/2020.05.05.20092015>

35. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. *BMJ*. 2020;369:m1966.
36. Long QX, Tang XJ, Shi QL, et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med*. 2020 Aug;26(8):1200-1204. doi: 10.1038/s41591-020-0965-6.
37. Regione Siciliana – Dipartimento Protezione Civile. Monitoraggio e mappatura dinamica dei contagi da COVID-19 in Sicilia. Available at: <https://www.protezionecivilesicilia.it/it/219-monitoraggio-e-mappatura-dinamica-dei-contagi-da-covid-19-nel-territorio-della-regione-sicilia.asp> (last accessed on September 4, 2021)
38. Regione Siciliana. Ordinanza contingibile e urgente n. 12 del 29.03.2020. Available at: [https://www.regione.sicilia.it/sites/default/files/2020-12/Ordinanza\\_n12\\_del\\_29032020.pdf](https://www.regione.sicilia.it/sites/default/files/2020-12/Ordinanza_n12_del_29032020.pdf) (last accessed on September 4, 2021)
39. EUROIMMUN Medizinische Labordiagnostika AG. Anti-SARS-CoV-2 ELISA. Manufacturer protocol. Available at: <https://www.euroimmun.com> (last accessed on September 4, 2021)
40. Okba N, Müller MA, et al. Severe Acute Respiratory Syndrome Coronavirus 2–Specific Antibody Responses in Coronavirus Disease Patients. *Emerg Infect Dis*. 2020;26(7):1478-1488.

## Supplementary Files



## Figures



## Troina study - Design.

